A Retrospective Chart Review Study to Assess the Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 15
- 主要终点
- Number of Critical Medical Assessments Related to LC-FAOD for Trigger Event
研究概览
简要总结
The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigational New Drug (eIND) program.
详细描述
The study is a retrospective chart review of patients in the USA with LC-FAOD who received triheptanoin via eIND request from their metabolic or treating physician before 01 September 2018. Participating study sites will provide the medical records of subjects who meet eligibility criteria, and relevant data regarding the trigger event (the reason the patient was placed on triheptanoin) and key details about hospitalizations during the study period will be extracted.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients of any age with confirmed diagnosis of one of the LC-FAOD disorders including: mitochondrial trifunctional protein (TFP) deficiency, carnitine palmitoyltransferase deficiencies (CPT I and CPT II), very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency, and carnitine acylcarnitine translocase (CATR) deficiency
- •Treatment initiation with triheptanoin was via eIND before 01 September 2018
- •Treated with triheptanoin in the USA
- •Willing and able to provide written, signed informed consent, or where appropriate for subjects under the age of 18, or provide written assent and written informed consent by a legally authorized representative after the nature of the study has been explained and prior to any research-related procedures. To obtain and review medical records of deceased individuals, informed consent from next of kin or appropriate legal entity will be obtained, as applicable.
排除标准
- •Unwilling to sign informed consent or assent to release of medical records
结局指标
主要结局
Number of Critical Medical Assessments Related to LC-FAOD for Trigger Event
时间窗: Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment
Duration of Important Interventions for Trigger Event
时间窗: Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment
Duration of Hospitalization for Trigger Event
时间窗: Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment
Disposition on Discharge of Trigger Event
时间窗: Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment
次要结局
- Disposition on Discharge of Other Major Clinical Events(Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment)
- Number of Critical Medical Assessments Related to LC-FAOD for Other Major Clinical Events(Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment)
- Number of Important Medical Interventions for Other Major Clinical Events(Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment)
- Duration of Hospitalization for Other Major Clinical Events(Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment)